AAVOLUTION

Having these facts in mind, our vital mission is to engineer the tissue tropism and immunogenicity of current AAV vectors. Vectors selected from clinically relevant models will serve as the platform for diverse applications from congenital to acquired diseases. Furthermore, our most interested disease types will be heart failure and hypertrophic cardiomyopathy due to their devastating influence in human populations and the dictating position of AAV vector development in their efficient treatment... AAVolutionGene therapy has brought us the unprecedented opportunity to treat congenital disorders. However, the current viral vectors were not created for gene delivery naturally. Significantly, although adeno-associated virus (AAV) has exhibited superior safety profile and efficacy in some clinical trials, nonspecific transduction or poor efficiency and pre-existing neutralizing antibodies are emerging as novel problems confronting the gene therapy community.

Also known as: AAV

Primary location: Chengdu China